Whole-life Investigation of Lishui Longevity

Sponsor
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
Study ID
NCT07592962
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 80 Years
Healthy Volunteers
Not accepted

Study Details

1. To establish a standardized, normalized and scientific joint screening and follow-up management system for chronic disease multimorbidity in Lishui City, and early identify common risk factors of major chronic diseases such as cardiovascular and cerebrovascular diseases and tumors. 2. To carry out targeted intervention and long-term follow-up for high-risk populations, reduce the incidence risk of major chronic diseases in the target population, improve residents' health status and grassroots comprehensive prevention and treatment capacity of chronic diseases, and provide scientific evidence and practical support for the construction of Healthy Lishui.

Key Dates

First listed
May 18, 2026
Start date
May 18, 2026
Status verified
May 2026
Primary completion
May 31, 2036
Completion
May 31, 2036

Study Design

Enrollment
4,500 participants (estimated)

Arms

  • Arm: Cerebrovascular group
    Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases.
  • Arm: Tumor Group
    The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population.
  • Arm: Epigenetic Age Group
    The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics.

Primary Outcome Measure

Prevalence rate of stroke and tumors [ Time Frame: From enrollment to the end of the 10-year follow-up period ]

Central Contacts

Find similar trials

Nationwide
Stroke trialsNeurology trialsBrain disorders trials

Related Studies